EUCTR2005-003592-20-ES进行中（未招募）1 期
Ensayo en fase II, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con docetaxel (Taxotereâ) frente a docetaxel solo como tratamiento de segunda línea del cáncer de mama avanzado (CMA).
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 65
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1. Provision of informed consent
- •2. Female patients aged 18 years or older
- •3. Females with histological/cytological confirmation of breast cancer
- •4. Patients fulfilling one of the following criteria: a) At least one measurable lesion as defined by Response Evaluation Criteria in Solid Tumours (RECIST); b) Patients with bone lesions, lytic or mixed (lytic + sclerotic), in the absence of measurable disease (as defined by RECIST).
- •5. Patients should have immunohistochemistry confirmed receptor negative breast cancer or patients who have failed hormonal treatment and who are only eligible for cytotoxic therapy
- •6. Patients who have failed either on or within 1 year of adjuvant therapy (excluding taxanes), or who have progressed on first line therapy for advanced disease (excluding taxanes)
- •7. WHO performance status (PS) 0 to2 and life expectancy >12 weeks. Patients with PS 3 will be eligible unless the Investigator believes the poor PS is predominantly due to co-existing morbidity (e.g. severe cardiac impairment)
- •8. Negative pregnancy test for women of child-bearing potential
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Treatment within 4 weeks before randomisation and/or whilst on study, treatment with the following: Non-approved or experimental drug; Chemotherapy, radiotherapy or other anticancer therapy
- •2. Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
- •3. Previous enrolment or randomisation of treatment in the present study
- •4. Previous definitive radiotherapy (e.g. to chest wall) within 6 weeks before randomisation
- •5. Any unresolved toxicity > Common Toxicity Criteria (CTC) grade 2 from previous anticancer therapy
- •6. History of hypersensitivity to active or inactive excipients of ZD6474, placebo or docetaxel
- •7. Major surgery within 4 weeks of randomisation, or incompletely healed surgical incision
- •8. Current or prior malignancy within previous 3 years (other than breast cancer or adequately treated basal cell or squamous cell carcinoma of the skin or in-situ carcinoma of the cervix).
- •9. Brain metastases or spinal cord compression, unless treated at least 4 weeks before entry, and stable without steroid treatment for 1 week
- •10. Any of the following laboratory values: Serum bilirubin greater than the upper limit of reference range (ULRR); Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than 1.5 x ULRR or alkaline phosphatase greater than 2.5 ULRR; Serum creatinine >1.5 x ULRR or creatinine clearance < or =50mL/minute (calculated by Cockcroft-Gault formula)
- •11. Any of the following laboratory values: platelets <100x10e9/L; absolute neutrophil count (ANC) <1.5 x 10e9/L
- •12. Potassium <4.0 mmol despite supplementation; serum calcium (or ionised or adjusted for albumin), or magnesium out of normal range despite supplementation
- •13. Significant cardiac event (e.g. myocardial infarction, superior vena cava syndrome, New York Heart Association classification of heart disease > or =2) within 3 months before entry, or presence of cardiac disease that, in the opinion of the investigator, increases the risk of ventricular arrhythmia
- •14. History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia, symptomatic or uncontrolled atrial fibrillation) which is symptomatic or requires treatment (CTC grade 3) or asymptomatic sustained ventricular tachycardia. Atrial fibrillation, controlled on medication is not excluded.
- •15. Congenital long QT syndrome or 1st degree relative with unexplained sudden death under 40 years of age
- •16. Previous QT prolongation with other medication that required discontinuation of that medication
- •17. Presence of left bundle branch block
- •18. QTc with Bazett’s correction unmeasurable or > or =480msec or greater on screening ECG (Note: if patient has QTc interval >or =480msec on screening ECG, the screen ECG may be repeated twice, at least 24 hours apart. The average QTc from the 3 screening ECGs must be <480msec for the patient to be eligible for the study)
- •19. Any concomitant medications that may cause QTc prolongation or induce Torsades de Pointes (as defined in the protocol)
- •20. Any severe concomitant condition which, in the Investigator’s opinion, makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the study protocol e.g. uncontrolled cardiac disease
- •21. Hypertension not controlled by medical therapy (systolic blood pressure >160 mmHg or diastolic blood pressure >110 mmHg)
- •22. Currently rec
研究者
相似试验
进行中（未招募）
不适用
Ensayo en fase IIa, aleatorizado, doble ciego, controlado con placebo y de comparación intra-individual entre los miembros izquierdo-derecho en 25 pacientes con dermatitis atópica moderada, para investigar la eficacia, irritación local, seguridad, tolerabilidad y farmacocinética de la aplicación tópica dos veces al día con crema ImCOOH al 10% durante 14 días y una aplicación adicional en el día 15. (Phase IIa, randomized, double-blind, placebo-controlled, intra-individual left-right limb comparison trial in 25 patients with moderate atopic dermatitis to investigate the efficacy, local irritation, safety, tolerability and pharmacokinetics of twice daily topical applications with 10% ImCOOH cream for 14 days with an additional morning application on Day 15.)dermatitis atópica (atopic dermatitis)MedDRA version: 9.1Level: LLTClassification code 10012438Term: Dermatitis atopicEUCTR2007-004011-54-ESValletta Health BV
进行中（未招募）
1 期
Ensayo en fase II, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de ZD6474 en combinación con Arimidexâ?frente a Arimidexâ?solo como tratamiento de segunda línea en pacientes con cáncer de mama avanzado (CMA) hormonosensible (receptores de estrógeno positivos y/o receptores de progesterona positivos).Cáncer de mama avanzado (CMA) hormono sensible (ER+ve y/o PR+ve)EUCTR2005-003591-38-ESAstraZeneca AB64
进行中（未招募）
1 期
Estudio para determinar la seguridad y eficacia de la inyección de recMAGE-A3 en pacientes con cáncer de vejiga musculo invasivo positivos a MAGE-A3 tras cistectomia.Patients who get a cystectomy due to muscle invasive bladder cancer which is MAGE-A3 positiveMedDRA version: 14.0Level: LLTClassification code 10022877Term: Invasive bladder cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-024355-85-ESEAU Research Foundation273
进行中（未招募）
不适用
Ensayo de fase 2, aleatorizado, en simple ciego y controlado con placebo, de la seguridad, la capacidad inmunógena y la tolerabilidad de la vacuna rLP2086 frente al meningococo de serogrupo B (MnB) a dosis de 60 microgramos, 120 microgramos y 200 microgramos en adolescentes sanos de 11 a 18 añosA Randomized, Single-Blind, Placebo-Controlled, Phase 2 Trial of the Safety, Immunogenicity, and Tolerability of Meningococcal Serogroup B (MnB) rLP2086 Vaccine at Doses of 60 micrograms, 120 micrograms, and 200 micrograms in Healthy Adolescents Aged 11 to 18 YearsVacuna rLP2086 frente al meningococo de serogrupo BThe test is a vaccine. The subjects are healthy adolescents.MedDRA version: 9.1Level: LLTClassification code 10027202Term: Meningitis bacterialEUCTR2008-007789-51-ESWyeth Research Division of Wyeth Pharmaceuticals Inc.715
进行中（未招募）
不适用
Ensayo de fase IIb, aleatorizado, doble ciego, controlado con placebo, para eltratamiento de la enfermedad celíaca activa con AT-1001Enfermedad celiaquia activaMedDRA version: 9.1Level: LLTClassification code 10007864Term: Celiac diseaseEUCTR2008-000415-14-ESAlba Therapeutics150